163 related articles for article (PubMed ID: 37743239)
1. Chronic lymphocytic leukaemia Australasian consensus practice statement.
Anderson MA; Bennett R; Badoux X; Best G; Chia N; Cochrane T; Cull G; Crassini K; Harrup R; Jackson S; Kuss B; Lasica M; Lew TE; Marlton P; Opat S; Palfreyman E; Polizzotto MN; Ratnasingam S; Seymour JF; Soosapilla A; Talaulikar D; Tam CS; Weinkove R; Wight J; Mulligan SP
Intern Med J; 2023 Sep; 53(9):1678-1691. PubMed ID: 37743239
[TBL] [Abstract][Full Text] [Related]
2. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
Di Ciaccio P; McCaughan G; Trotman J; Ho PJ; Cheah CY; Gangatharan S; Wight J; Ku M; Quach H; Gasiorowski R; Polizzotto MN; Prince HM; Mulligan S; Tam CS; Gregory G; Hapgood G; Spencer A; Dickinson M; Latimer M; Johnston A; Armytage T; Lee C; Cochrane T; Berkhahn L; Weinkove R; Doocey R; Harrison SJ; Webber N; Lee HP; Chapman S; Campbell BA; Gibbs SDJ; Hamad N
Intern Med J; 2020 Jun; 50(6):667-679. PubMed ID: 32415723
[TBL] [Abstract][Full Text] [Related]
3. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Weinkove R; McQuilten ZK; Adler J; Agar MR; Blyth E; Cheng AC; Conyers R; Haeusler GM; Hardie C; Jackson C; Lane SW; Middlemiss T; Mollee P; Mulligan SP; Ritchie D; Ruka M; Solomon B; Szer J; Thursky KA; Wood EM; Worth LJ; Yong MK; Slavin MA; Teh BW
Med J Aust; 2020 Jun; 212(10):481-489. PubMed ID: 32401360
[TBL] [Abstract][Full Text] [Related]
6. Management of relapsed/refractory Chronic Lymphocytic Leukemia.
Woyach JA
Am J Hematol; 2022 Nov; 97 Suppl 2(Suppl 2):S11-S18. PubMed ID: 36125037
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
Hanna KS; Fijalka A; Watson I; Brown O; Ojulu A
J Oncol Pharm Pract; 2022 Dec; 28(8):1869-1884. PubMed ID: 35635742
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
Eyre TA; Hori S; Munir T
Hematol Oncol; 2022 Apr; 40(2):129-159. PubMed ID: 34713475
[TBL] [Abstract][Full Text] [Related]
10. Expert consensus on the management of chronic lymphocytic leukaemia in Asia.
Tse E; Kwong YL; Goh YT; Bee PC; Ng SC; Tan D; Caguioa P; Nghia H; Dumagay T; Norasetthada L; Chuncharunee S; Radhakrishnan V; Bagal B; Atmakusuma TD; Mulansari NA
Clin Exp Med; 2023 Oct; 23(6):2895-2907. PubMed ID: 36795237
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
12. Combined chronic myeloid leukaemia and chronic lymphocytic leukaemia in five patients, including one with 17p deletion.
Armarego M; Gottlieb D; Dunlop L; Cooney JP
Intern Med J; 2021 Apr; 51(4):580-584. PubMed ID: 33890366
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
14. Practical management of chronic lymphocytic leukemia with acalabrutinib.
Kuss B; Nagarajan C; Hsieh WS; Cheah CY
Leuk Lymphoma; 2022 Dec; 63(12):2785-2794. PubMed ID: 35852229
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
D'Souza P; Walker G
Drugs Today (Barc); 2014 Jul; 50(7):485-501. PubMed ID: 25101331
[TBL] [Abstract][Full Text] [Related]
17. [Molecular pathogenesis and treatment of chronic lymphocytic leukemia].
Suzuki R
Rinsho Ketsueki; 2021; 62(8):1085-1093. PubMed ID: 34497195
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Mulligan SP; Opat S; Cheah CY; Kuss B; Hertzberg M; Marlton P; Poplar S; Puig A; McGeachie M; Weinkove R; Tam CS
Leuk Lymphoma; 2023 Feb; 64(2):312-318. PubMed ID: 36423351
[TBL] [Abstract][Full Text] [Related]
19. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Chanan-Khan AA; Coutre SE; Davis RS; Eradat H; Fletcher CD; Gaballa S; Ghobadi A; Hamid MS; Hernandez-Ilizaliturri F; Hill B; Kaesberg P; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Ma S; Mato A; Mosse C; Schuster S; Siddiqi T; Stephens DM; Ujjani C; Wagner-Johnston N; Woyach JA; Ye JC; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2022 Jun; 20(6):622-634. PubMed ID: 35714675
[TBL] [Abstract][Full Text] [Related]
20. Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?
Smith CIE; Zain R; Österborg A; Palma M; Buggert M; Bergman P; Bryceson Y
Scand J Immunol; 2022 Apr; 95(4):e13153. PubMed ID: 35244285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
